From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the glioma pharmaceutical market based on detailed primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods. 

Questions Answered:

  • How large is the treatable glioma population, and how will diagnosis/drug-treatment rates change over time?
  • What is the current state of treatment in glioma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in glioma? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the glioma market, and how will the market evolve over the forecast period?


Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with thought leaders.

Epidemiology: Diagnosed incident cases of low-grade glioma (WHO grade I-II), high-grade glioma (anaplastic glioma; WHO grade III), glioblastoma (WHO grade IV; primary cases ), and transformed cases of nonglioblastoma astrocytic glioma (WHO grade I-III; secondary cases).

Population segments in market forecast: First-line glioblastoma (newly diagnosed and transformed nonglioblastoma astrocytic glioma cases), second-line glioblastoma (first recurrence), and third-line glioblastoma (second recurrence).

Phase III: 6 drugs; Phase II: 15 drugs; coverage of selected preclinical and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
      • Note About Our Epidemiology Estimates
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Market Overview
      • Drivers and Constraints
        • What Factors Are Driving the Market for Glioma
        • What Factors Are Constraining the Market for Glioma
      • Segment-Specific Trends
        • Newly Diagnosed
        • Recurrent
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
        • Expert Insight
      • Etiology
      • Disease Pathophysiology
        • Grading and Histological Classification
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Overview
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Histology
        • Transformed Cases of Astrocytic Glioma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Treatment Overview
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
        • Key Physician Insights on Clinical End Points
        • Response Assessment Criteria for Glioblastoma
      • Key Current Therapies
        • Overview
        • Cytotoxic Agents
        • Optune
        • VEGF Inhibitors
        • VEGF Inhibitors
      • Medical Practice
        • Drug-Treatable Population: Low-Grade Glioma
        • Drug-Treatable Population: Anaplastic Glioma
        • Drug-Treatable Population: Newly Diagnosed Glioblastoma
        • Drug-Treatable Population: Recurrent Glioblastoma
        • Region-Specific Treatment
        • Treatment Guidelines
    • Unmet Need Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Glioma
        • Future Attainment of Unmet Needs in Glioma
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Pipeline Overview
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for Glioma
      • Orphan-Drug Designation
        • Orphan-Drug Provisions: United States
        • Orphan-Drug Provisions: Europe
      • Patient Registries
        • Patient Organizations
      • Key Emerging Therapies
        • Dendritic-Cell Vaccines
        • Viral Therapies
        • Immune Checkpoint Inhibitors
        • Antibody-Drug Conjugate
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
      • U.S. Reimbursement Dynamics
      • U.S. Access & Reimbursement Considerations for Emerging Therapies
        • Access & Reimbursement Considerations for Emerging Glioblastoma Therapies in the United States
    • Methodology
      • Methodology
        • Bottom-Up Forecasting Overview
        • Patient Share and Sales Calculations
        • Drug-Treatment Rate Assumptions in Glioma
        • Patient Share Assumptions in Glioma
        • General Sources of Data
        • Dosing, Cycles of Therapy, and Compliance
        • Biosimilar Erosion
        • Price per Cycle and Course Assumptions, 2015
        • Price per Cycle and Course Assumptions, 2025
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Aarushi Kashyap, M.Tech

Aarushi Kashyap is a Senior Insights Analyst in Oncology team at Decision Resources Group, based out of Gurgaon office in India. She comes with a work experience of 4 years as Business Analyst with practice across multiple oncology indications in various functions in Competitive Intelligence and Secondary Research, including pipeline analysis, competitive product reporting, clinical trials assessment and benchmarking, clinical and competitor landscaping, therapy area deep dive reporting, ad-hoc news tracking etc. She has attended various big and small oncology medical congresses across US and Europe in parallel to creating pre- and post-conference data summaries with implications and schedule trackers for abstracts of interest delivering to directly to clients. She has earned her Master's and Bachelor's in Technology in Biotechnology from Jaypee Institute of Information Technology University.

Related Reports

Glioma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of glioma&nb...

View Details

Glioma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key glioma patient populations...

View Details